Approval Criteria for formulary SGLT2 Inhibitors
Customize your policy alerts
Sign up for allcareadvantage Policy 026.6 alerts
Get alerted when Policy 026.6 changes without checking for updates manually.
Monitor payer policy activity
Defines AllCare Advantage coverage, prior authorization, and renewal criteria for formulary and non-formulary SGLT2 inhibitor drugs for treatment of type 2 diabetes, including special considerations for heart failure and chronic kidney disease.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.